Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) EBT (2016 - 2025)

Historic EBT for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to -$2.7 million.

  • Evogene's EBT rose 5956.72% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year increase of 6328.66%. This contributed to the annual value of -$14.8 million for FY2024, which is 4301.77% up from last year.
  • Per Evogene's latest filing, its EBT stood at -$2.7 million for Q3 2025, which was up 5956.72% from -$3.5 million recorded in Q2 2025.
  • Over the past 5 years, Evogene's EBT peaked at $990000.0 during Q4 2024, and registered a low of -$9.7 million during Q2 2022.
  • Its 5-year average for EBT is -$5.8 million, with a median of -$6.9 million in 2021.
  • Per our database at Business Quant, Evogene's EBT crashed by 9441.21% in 2023 and then soared by 11348.59% in 2024.
  • Over the past 5 years, Evogene's EBT (Quarter) stood at -$8.1 million in 2021, then skyrocketed by 53.33% to -$3.8 million in 2022, then crashed by 94.41% to -$7.3 million in 2023, then soared by 113.49% to $990000.0 in 2024, then plummeted by 375.56% to -$2.7 million in 2025.
  • Its EBT was -$2.7 million in Q3 2025, compared to -$3.5 million in Q2 2025 and -$3.0 million in Q1 2025.